SC Pharmaceuticals Inc (SCPH)

$2.51 +0.01 (0.40%)
Market Cap 126.21M
Revenue (ttm) 36.33M
Net Income (ttm) -85.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -234.38%
Debt to Equity Ratio 3.86
Volume 249,200
Avg Vol 513,062
Day's Range N/A - N/A
Shares Out 50.28M
Stochastic %K 52%
Beta 0.38
Analysts Strong Sell
Price Target $15.17

Latest News on SCPH

scPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 7:13 PM EDT - 5 weeks ago

scPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call Transcript

scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 4:01 PM EDT - 5 weeks ago

scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025

Mar 12, 2025, 4:01 PM EDT - 6 weeks ago

scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease

Mar 6, 2025, 4:01 PM EST - 7 weeks ago

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease

scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences

Feb 26, 2025, 4:01 PM EST - 2 months ago

scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences

scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 4:01 PM EST - 2 months ago

scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

Jan 10, 2025, 8:00 AM EST - 3 months ago

scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

scPharmaceuticals Inc. (SCPH) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:05 PM EST - 5 months ago

scPharmaceuticals Inc. (SCPH) Q3 2024 Earnings Call Transcript

scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 13, 2024, 4:01 PM EST - 5 months ago

scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

Nov 6, 2024, 4:01 PM EST - 6 months ago

scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024

Oct 15, 2024, 8:30 AM EDT - 6 months ago

scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024

scPharmaceuticals Inc. (SCPH) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 5:10 AM EDT - 9 months ago

scPharmaceuticals Inc. (SCPH) Q2 2024 Earnings Call Transcript

scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 4:01 PM EDT - 9 months ago

scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

scPharmaceuticals Announces Pricing of $50.0 Million Public Offering

Aug 12, 2024, 9:48 AM EDT - 9 months ago

scPharmaceuticals Announces Pricing of $50.0 Million Public Offering

scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors

Aug 12, 2024, 6:05 AM EDT - 9 months ago

scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure

Aug 12, 2024, 6:04 AM EDT - 9 months ago

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure

scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector

Aug 12, 2024, 6:02 AM EDT - 9 months ago

scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector

scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Aug 12, 2024, 6:00 AM EDT - 9 months ago

scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

scPharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 29, 2024, 4:01 PM EDT - 11 months ago

scPharmaceuticals to Present at the Jefferies Global Healthcare Conference

scPharmaceuticals Inc. (SCPH) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:02 PM EDT - 1 year ago

scPharmaceuticals Inc. (SCPH) Q1 2024 Earnings Call Transcript

scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 4:01 PM EDT - 1 year ago

scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 4:05 PM EDT - 1 year ago

scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024

May 7, 2024, 4:05 PM EDT - 1 year ago

scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection

Apr 24, 2024, 8:00 AM EDT - 1 year ago

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection

scPharmaceuticals Inc (SCPH) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 7:32 PM EDT - 1 year ago

scPharmaceuticals Inc (SCPH) Q4 2023 Earnings Call Transcript

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Mar 13, 2024, 4:01 PM EDT - 1 year ago

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024

Mar 6, 2024, 4:01 PM EST - 1 year ago

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

Feb 28, 2024, 4:01 PM EST - 1 year ago

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

Jan 4, 2024, 4:05 PM EST - 1 year ago

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

scPharmaceuticals Q3 Earnings: Cruising Toward Success

Nov 12, 2023, 2:57 AM EST - 1 year ago

scPharmaceuticals Q3 Earnings: Cruising Toward Success

scPharmaceuticals Inc (SCPH) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 9:58 PM EST - 1 year ago

scPharmaceuticals Inc (SCPH) Q3 2023 Earnings Call Transcript

scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 4:01 PM EST - 1 year ago

scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

Nov 1, 2023, 4:05 PM EDT - 1 year ago

scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 5, 2023, 8:00 AM EDT - 1 year ago

scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

scPharmaceuticals: Furoscix, Charting A Bright Future With FDA's Nod For CKD

Sep 27, 2023, 12:40 AM EDT - 1 year ago

scPharmaceuticals: Furoscix, Charting A Bright Future With FDA's Nod For CKD

scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives

Sep 19, 2023, 8:00 AM EDT - 1 year ago

scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives

Sizing Up scPharmaceuticals

Sep 13, 2023, 2:13 PM EDT - 1 year ago

Sizing Up scPharmaceuticals

scPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:00 AM EDT - 1 year ago

scPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

scPharmaceuticals Inc. (SCPH) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 10:38 PM EDT - 1 year ago

scPharmaceuticals Inc. (SCPH) Q2 2023 Earnings Call Transcript

scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 4:01 PM EDT - 1 year ago

scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Aug 3, 2023, 8:00 AM EDT - 1 year ago

scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023

scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion

Aug 1, 2023, 8:00 AM EDT - 1 year ago

scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion

scPharmaceuticals: Oversold Territory, Drug Launch Still Looks Robust

Jun 29, 2023, 11:05 PM EDT - 1 year ago

scPharmaceuticals: Oversold Territory, Drug Launch Still Looks Robust

scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes

Jun 23, 2023, 8:00 AM EDT - 2 years ago

scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes

scPharmaceuticals to Present at the Jefferies Healthcare Conference

May 31, 2023, 8:00 AM EDT - 2 years ago

scPharmaceuticals to Present at the Jefferies Healthcare Conference

scPharmaceuticals: Furoscix Firing On All Cylinders In Q1, Bullish Than Ever

May 20, 2023, 12:15 AM EDT - 2 years ago

scPharmaceuticals: Furoscix Firing On All Cylinders In Q1, Bullish Than Ever

scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023, 4:01 PM EDT - 2 years ago

scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

scPharmaceuticals to Announce First Quarter 2023 Financial Results on Wednesday, May 10, 2023

May 2, 2023, 8:00 AM EDT - 2 years ago

scPharmaceuticals to Announce First Quarter 2023 Financial Results on Wednesday, May 10, 2023

scPharmaceuticals Inc. (SCPH) Q4 2022 Earnings Call Transcript

Mar 22, 2023, 8:11 PM EDT - 2 years ago

scPharmaceuticals Inc. (SCPH) Q4 2022 Earnings Call Transcript

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Mar 22, 2023, 4:05 PM EDT - 2 years ago

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update